Skip to content
  • Home
  • How We Work
    • The Impact of Autophagy in Health and Disease
    • Biophagy’s Business Model
    • Biophagy’s Proprietary Drug Development
    • Cell Watchᵀᴹ
  • Business Development
  • Background & News
  • Team
  • Contact
Previous Next

Biophagy announces the granting of a USPTO composition-of-matter patent for several compounds in its BPY-100 series. These proprietary molecules have shown activity in assays related to tuberculosis, covid-19, and neurodegenerative disorders.

By jordan|2022-03-22T20:35:45+00:00February 1, 2022|2021-announcements|0 Comments

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: jordan

Related Posts

  • Biophagy is awarded a STEP grant through the NM Department of Economic Development for upgrading its website. This will help attract international partners and collaborators.

    Biophagy is awarded a STEP grant through the NM Department of Economic Development for upgrading its website. This will help attract international partners and collaborators.

  • Biophagy initiates a collaboration with Dr. Ramesh Jha, Los Alamos National Laboratories, to study its antiviral compounds using molecular docking. This will help determine ligand affinity and specificity for use in lead development.

    Biophagy initiates a collaboration with Dr. Ramesh Jha, Los Alamos National Laboratories, to study its antiviral compounds using molecular docking. This will help determine ligand affinity and specificity for use in lead development.

Leave A Comment Cancel reply

Copyright 2022 | All Rights Reserved | Website Design and Development by Ingenuity Software Labs
FacebookTwitterInstagramPinterest
Page load link
Go to Top